选择性TYK2抑制剂deucravacitinib治疗银屑病关节炎的II期试验疗效与安全性
这项双盲II期试验将203例活动性银屑病关节炎患者按1:1:1随机分配至安慰剂组、deucravacitinib 6 mg每日一次组或12 mg每日一次组,主要终点为第16周ACR-20应答。结果显示6 mg组(52.9%,p=0.0134)和12 mg组(62.7%,p=0.0004)的ACR-20应答率均显著高于安慰剂组(31.8%),两种剂量在多重控制的次要终点上也显著优于安慰剂,最常见不良事件为鼻咽炎、上呼吸道感染等,未发生严重不良事件。
要点
- 第16周ACR-20应答率:deucravacitinib 6 mg组52.9%(p=0.0134)、12 mg组62.7%(p=0.0004),均显著高于安慰剂组31.8%。
- 两种剂量在HAQ-DI、SF-36 PCS评分变化和PASI-75应答等多重控制次要终点上均显著优于安慰剂(p≤0.05)。
- deucravacitinib治疗组最常见不良事件(≥5%)为鼻咽炎、上呼吸道感染、鼻窦炎、支气管炎、皮疹、头痛和腹泻,未发生严重不良事件。
核心结论
- 选择性TYK2抑制剂deucravacitinib耐受性良好,在ACR-20、多重控制次要终点及其他探索性疗效指标上较安慰剂带来更大改善。
- 作者认为需要更大规模、更长周期的试验来确认deucravacitinib在银屑病关节炎中的安全性和获益。
研究设计与样本
- 双盲II期试验,203例活动性银屑病关节炎患者按1:1:1随机分配至安慰剂组、deucravacitinib 6 mg每日一次组或12 mg每日一次组。
- 主要终点为第16周美国风湿病学会20(ACR-20)应答率。
主要发现
- 第16周ACR-20应答率:deucravacitinib 6 mg组52.9%(p=0.0134)、12 mg组62.7%(p=0.0004),均显著高于安慰剂组31.8%。
- 两种剂量在HAQ-DI和SF-36 PCS评分较基线变化以及PASI-75应答等多重控制次要终点上均显著优于安慰剂(p≤0.05)。
- deucravacitinib治疗在多个探索性终点上也观察到改善。
- deucravacitinib治疗组最常见不良事件(≥5%)为鼻咽炎、上呼吸道感染、鼻窦炎、支气管炎、皮疹、头痛和腹泻。
- deucravacitinib治疗未发生严重不良事件,未发生带状疱疹、机会性感染和主要不良心血管事件,实验室参数平均变化与安慰剂无差异。
关键数值与推荐
- ACR-20应答率:deucravacitinib 6 mg组52.9%(p=0.0134)vs 安慰剂组31.8%,6 mg组显著高于安慰剂组。
- ACR-20应答率:deucravacitinib 12 mg组62.7%(p=0.0004)vs 安慰剂组31.8%,12 mg组显著高于安慰剂组。
- 多重控制次要终点(HAQ-DI和SF-36 PCS评分较基线变化、PASI-75应答):两种deucravacitinib剂量均显著优于安慰剂(p≤0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要更大规模、更长周期的试验来确认deucravacitinib在银屑病关节炎中的安全性和获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). METHODS: In this double-blind, phase II trial, 203 patients with PsA were randomised 1:1:1 to placebo, deucravacitinib 6 mg once a day or 12 mg once a day. The primary endpoint was American College of Rheumatology-20 (ACR-20) response at week 16. RESULTS: ACR-20 response was significantly higher with deucravacitinib 6 mg once a day (52.9%, p=0.0134) and 12 mg once a day (62.7%, p=0.0004) versus placebo (31.8%) at week 16. Both deucravacitinib doses resulted in significant improvements versus placebo (p≤0.05) in the multiplicity-controlled secondary endpoints of change from baseline in Health Assessment Questionnaire-Disability Index and Short Form-36 Physical Component Summary score and in Psoriasis Area and Severity Index-75 response. Improvements were also seen in multiple exploratory endpoints with deucravacitinib treatment. The most common adverse events (AEs) (≥5%) in deucravacitinib-treated patients were nasopharyngitis, upper respiratory tract infection, sinusitis, bronchitis, rash, headache and diarrhoea. There were no serious AEs and no occurrence of herpes zoster, opportunistic infections and major adverse cardiovascular events, or differences versus placebo in mean changes in laboratory parameters with deucravacitinib treatment. CONCLUSIONS: Treatment with the selective TYK2 inhibitor deucravacitinib was well tolerated and resulted in greater improvements than placebo in ACR-20, multiplicity-controlled secondary endpoints and other exploratory efficacy measures in patients with PsA. Larger trials over longer periods of time with deucravacitinib are warranted to confirm its safety profile and benefits in PsA. TRIAL REGISTRATION NUMBER: NCT03881059.
引用
- Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022. PMID: 35241426. doi:10.1136/annrheumdis-2021-221664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。